Inclisiran
Inclisiran 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Heterozygous or Homozygous Familial Hypercholesterolemia。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
22 项
全球在招研究
10 项
已进入 III/IV 期
30 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Novartis Pharmaceuticals
- Nanjing First Hospital, Nanjing Medical University
- University of California, San Diego
- Third Military Medical University
- Yun Dai Chen
- University of Colorado, Denver
- University Medical Centre Ljubljana
- Federico II University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、South Korea、Russia、奥地利、德国、Greece、Malaysia、荷兰、South Africa、中国台湾、Turkey (Türkiye)
正在招募患者的 Inclisiran 研究
Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques
IV 期招募中中国NCT06338293LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
IV 期招募中美国NCT06865885Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
不适用招募中South KoreaNCT06770543Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients
不适用招募中RussiaNCT07142265Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
不适用招募中RussiaNCT06858332Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
III 期招募中美国奥地利中国德国NCT06597006A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab
不适用招募中瑞士NCT07543731Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
III 期招募中美国ArgentinaBrazil加拿大NCT05682378Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
III 期招募中美国Argentina奥地利比利时NCT06597019LATAM LOWERS LDL-C
IV 期招募中ArgentinaBrazilNCT06501443Comparing Inclisiran Versus Statin for Primary Aldosteronism
不适用招募中中国NCT07884955Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
I 期招募中美国NCT07626281Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
III 期招募中Argentina澳大利亚加拿大中国NCT07102628Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
不适用招募中中国NCT06738758Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
不适用招募中美国NCT07704918Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
IV 期招募中SloveniaNCT07581808A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
II 期招募中美国NCT07610278Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy
不适用招募中意大利NCT06287177Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
不适用招募中英国NCT06126367The Prevent Coronary Artery Disease Trial
III 期招募中美国NCT06494501Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
II 期招募中中国NCT07803822Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
IV 期招募中美国NCT06909565
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。